A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

NCT03320629 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped This study was voluntarily terminated after investigator assessment, with no safety concerns identified related to the trial intervention or procedures. The primary reason for termination was difficulty in patient recruitment.

Conditions

Refractory or Metastatic Esophageal Squamous Cell Carcinoma

Interventions

COMBINATION_PRODUCT: apatinib S-1 radiotherapy
COMBINATION_PRODUCT: S-1 radiotherapy

Sponsor

Hebei Medical University Fourth Hospital